Evidence map›Paper›PMID 40539043›Full record

ArticleFrontiers in immunology2025

Leah Kashiri, Wonderful T Choga, Tinashe Musasa, Pasipanodya Nziramasanga, Rutendo B Gutsire, Lynn S Zijenah, Norman L Mukarati, Simani Gaseitsiwe, Sikhulile Moyo, Nyasha Chin'ombe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Vaccine development againstClinical and experimental vaccine research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leah KashiriMedical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Wonderful T ChogaDepartment of Medical Sciences, Botswana Harvard Health Partnership, Gaborone, Botswana.
Tinashe MusasaMedical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Pasipanodya NziramasangaMedical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Rutendo B GutsireImmunology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Lynn S ZijenahImmunology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Norman L MukaratiDepartment of Clinical Veterinary Sciences, Faculty of Veterinary Sciences, University of Zimbabwe, Harare, Zimbabwe.
Simani GaseitsiweDepartment of Medical Sciences, Botswana Harvard Health Partnership, Gaborone, Botswana.
Sikhulile MoyoDepartment of Medical Sciences, Botswana Harvard Health Partnership, Gaborone, Botswana.
Nyasha Chin'ombeMedical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Methods: From a genomic survey of nontuberculous mycobacteria (NTM) in Zimbabwe, we assembled complete genomes for Results: Epitope mapping across the nine target proteins yielded 82 THL epitopes predicted to bind 13 MHC class II (DRB*) alleles, ensuring broad coverage within Zimbabwean and pan-African populations. Clustering analyses consolidated 26 unique epitopes into 11 consensus peptides, 65.4% of which derived from the 85B proteins. Conclusion: These findings indicate that our construct possesses strong immunogenic potential and cross-species applicability. We present here a rationally designed MEV candidate that merits further experimental validation as a broad-spectrum vaccine against multiple MAC species.

Indexed as

Bacterial VaccinesEpitopes, T-LymphocyteMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAntigens, BacterialComputer SimulationEpitope MappingHumansImmunogenicity, VaccineVaccine DevelopmentAntigens, BacterialBacterial VaccinesEpitopes, T-LymphocyteAntigen85EpitopesimmunodominanceMycobacterium avium complexmycolyltransferasepromiscuous epitopesTh1 helper T-cellVaccine

Identifiers

PMID40539043
PMCPMC12176759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.